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A B S T R A C T
Kidney diseases are serious public problems with high morbidity and mortality in the general population and
heavily retard renal function with aging regardless of the cause. Although myriad strategies have been assigned
to prevent or harness disease progression, unfortunately, thus far, there is a paucity of eﬀective therapies partly
due to an insuﬃcient knowledge of underlying pathological mechanisms, indicating deeper studies are urgently
needed. Additionally, natural products are increasingly recognized as an alternative source for disease inter-
vention owing to the potent safety and eﬃcacy, which might be exploited for novel drug discovery. In this
review, we primarily expatiate the new advances on mediators that might be amenable to targeting aging kidney
and kidney diseases, including nicotinamide adenine dinucleotide phosphate oxidase (NOX), transforming
growth factor-β (TGF-β), renin-angiotensin system (RAS), nuclear factor-erythroid 2 related factor 2 (Nrf2),
peroxisome proliferator-activated γ receptor (PPARγ), advanced glycation endproducts (AGEs) as well as
microRNAs and vitagenes. Of note, we conclude by highlighting some natural products which have the potential
to facilitate the development of novel treatment for patients with myriad renal diseases.
1. Introduction
Kidney diseases remain major health problems with a high pre-
valence around the world and a variety of pathophysiological processes
are implicated in the progression [1–3]. Oxidative stress is a patholo-
gical condition that reactive oxygen species (ROS) generation far ex-
ceeds the scavenging capacity of anti-oxidant defense systems, which
plays a particularly pivotal role in the pathogenesis of myriad renal
disorders [4–6]. Given the few and limited eﬃcacy of current therapies
for renal diseases, normalization of ROS utilizing mechanism-based
intervention represents a promising alternative towards arresting
kidney disease progression [7–11].
Mounting evidence revealed that a series of physiological processes
that devoted much to ROS production were previously published in
detail, such as hexosamine pathway activation, protein kinase C upre-
gulation, polyol pathway alteration and autonomic nervous system
hyperactivation [4,12,13]. Here we only brieﬂy emphasize the recent
advances in mediators of ROS generation that were closely associated
with the regulation of kidney with aging and pathological conditions
for the sake of brevity, including nicotinamide adenine dinucleotide
phosphate oxidase (NOX), transforming growth factor-β (TGF-β), renin-
angiotensin system (RAS), nuclear factor-erythroid 2 related factor 2
(Nrf2), peroxisome proliferator-activated γ receptor (PPARγ), advanced
glycation endproducts (AGEs) as well as microRNAs and vitagenes
(Fig. 1). ROS is of paramount signiﬁcance to disease progression and a
thorough understanding of these mediators will pave the way to the
booming development of therapies against kidney diseases since they
play vital roles in redox signaling.
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In addition, some commercial drugs approved by FDA were reported
to show serious side eﬀects, which severely impeded their clinical use,
hinting new drugs and strategies are urgently needed [14–16]. In this
review, we highlight a number of natural products that could target the
above-mentioned mediators as exempliﬁed by 25-O-methylalisol F
[17], poricoic acid ZA [18] and salvianolic acid A [19], which might
provide novel therapeutic strategy for the treatment of renal diseases.
2. Oxidative stress associated novel mediators in aging kidney and
renal diseases
2.1. NOX signaling
Myriad enzymes contribute to ROS generation, of which NOX family
is dedicated generators of intracellular superoxide and hydrogen that
strongly involve in redox signaling under healthy and pathological
conditions [20–22]. NOX family consists of ﬁve isoforms including
NOX1, NOX2, NOX3, NOX4 and NOX5, which accelerate ROS produc-
tion in the vasculature [23–27]. In this scenario, we shift the concept to
NOX4 as a critical driver for various renal disorders since NOX4 is most
plentiful in kidney [28–30].
In the kidney, ﬁbrosis is the pathologic extension of wound healing
process response to chronic or repeated injuries, which represents a
common pathway of nearly all progressive renal diseases regardless of
the etiology, and may ultimately lead to architecture disruption and
function loss [31,32]. Wound healing generally proceeds through three
periods that are provisional overlapping but functionally distinct, in-
cluding the initial inﬂammatory phase as well as proliferative phase
and maturation phase [31,33]. The provisional extracellular matrix
exacerbated by ﬁbrogenic cytokine undergoes degradation and facil-
itates tissue remodeling, the dysregulation of which or persistent
chronic injury permits adequate opportunity for the formation of ﬁ-
brotic lesion [34–36]. Although ﬁbrosis was previously recognized as
an irreversible progress [37], emerging evidence demonstrated that
certain circumstances allowed ﬁbrosis resolution when the underlying
preventable causes of ﬁbrogenesis were eradicated [38–40]. NOX-de-
rived ROS were intimately involved in numerous organ ﬁbrosis such as
heart, liver, lung and kidney [41–43], particularly for NOX4 in the
nephropathic milieu, which was recognized as the most abundant
isoforms in renal proximal tubular epithelial cells [29]. A reduction of
NOX4 expression by carnosic acid treatment has been proved to protect
against unilateral ureteral obstruction-induced renal ﬁbrosis, fueling
considerable enthusiasm for NOX4 blockade as an attractive therapy
[44]. However, sustained controversy about the role of NOX4 sup-
pression on alleviating ﬁbrogenesis existed as NOX4 deletion was as-
sociated with ﬁbrosis acceleration as well [45]. In addition, ROS ele-
vation may act as a potent signal for accelerated senescence [46] and
NOX4 was strongly associated with advanced age since it facilitated
wound healing and myoﬁbroblast diﬀerentiation in young animal
models whereas exacerbated substantial ﬁbrosis in aged mice. More-
over, the consensus that NOX4 acted as a key mediator of glomerular
dysfunction in hyperglycemic milieu through modulating fumarate
hydratase is increasingly recognized as an emerging mechanism of
diabetic kidney disease [47], highlighting the importance of NOX4 in-
hibition in the treatment of diabetic nephropathy [29].
NOX also played a decisive role in the initiation and progression of
tumorigenesis [48,49] via mediating redox homeostasis. NOX4 pro-
moted renal tumorigenesis through the expression and accumulation of
hypoxia inducible factor expression, which was triggered by tran-
scriptional and post-translational mechanisms [50]. Of note, angio-
genesis accelerated tumor growth and NOX4 contributed to renal tu-
morigenesis by modulating angiogenesis as well, indicating NOX4 is a
potential target for therapeutic exploitation [51]. Nevertheless, owing
to the corresponding studies of NOX4 in cancer are still in the infancy,
deeper mechanistic understand of NOX4 in renal tumor remains to be
determined.
2.2. TGF-β/Smad signaling
As we reﬂect on relevant investigations as well as summarize the
accumulating ﬁndings, it is generally acknowledged that oxidative
stress had a pivotal role in myriad kidney diseases besides inﬂammatory
milieu, underscoring the potential of ROS eradication in the develop-
ment of novel therapeutic strategies [52–54]. TGF-β and its receptor-
small mother against decapentaplegic (Smad) are of critical importance
to kidney ﬁbrosis through myoﬁbroblast diﬀerentiation and in-
ﬂammatory cytokine accumulation [55]. Additionally, a growing body
of evidence revealed that TGF-β was implicated in oxidative stress and
Fig. 1. The mainly molecular mechanisms and their
cross-talk of redox signaling in aging kidney and
kidney disease. Myriad enzymes contribute to ROS
generation, of which NOX family is dedicated gen-
erators of intracellular superoxide and hydrogen that
strongly involve in redox signaling. RAS elements are
of paramount importance to TGF-β/Smad signaling
activation, which play pivotal roles in ROS genera-
tion through NOX4 regulation. Additionally, AGE-
RAGE signaling pathway is also implicated in oxi-
dative stress progression by mediating NOX4. Of
note, PPARγ and Nrf2 show protective potential
against oxidative stress via inhibiting TGF-β/Smad
and promoting anti-oxidant responses, respectively.
AGT, angiotensinogen; ANG I, angiotensin I; ANG II,
angiotensin II; AT1, angiotensin II type 1 receptor;
AT2, angiotensin II type 2 receptor; ERK, extra-
cellular signal-related kinase; HO, haem oxygenase;
MEK, mitogen-activated protein kinase/extracellular
signal-related kinase; NQO1, NAD(P)H dehy-
drogenase (Quinone) 1; SARA, smad anchor for re-
ceptor activation.
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NOX4 was most accountable for TGF-β-induced ROS generation
through a TGF-β/Smad/ROS signaling cascade [56,57]. The most
compelling evidence of ﬁbrogenesis resolution associated with TGF-β/
NOX4 in human beings was observed in the lung. Mounting studies
highlighted that NOX4 was upregulated in response to TGF-β among
patients with idiopathic pulmonary ﬁbrosis [58] and therapeutic
treatment with NOX4 inhibition mediated by the enhancement of
proteasomal degradation [59] or small interfering RNA [60] could at-
tenuate the progression of ﬁbrogenesis. Unfortunately, thus far, the
underlying mechanism of TGF-β and NOX4 in humans and animal
models of renal ﬁbrosis remains elusive and a deeper elucidation is
essential to preventing or harnessing kidney complications.
2.3. RAS
Another severe consequence of excessive ROS in intrarenal cells is
the activation of RAS and its related elements [61], a better under-
standing of which may facilitate the exploitation of eﬀective ther-
apeutic strategies for patients with renal disease. RAS has the potential
to trigger renal ﬁbrosis and RAS activation is induced by ROS directly
or mediated via AGEs generation. All of RAS components exist in renal
tissues, including renin, angiotensinogen, angiotensin converting en-
zyme, angiotensin II, angiotensin II type 1 receptors and angiotensin II
type 2 receptors, and ﬁbrosis can evidently seize control of angiotensin
II to deteriorate ﬁbrogenesis via stimulating TGF-β expression or
phosphorylating Smad2 and Smad3 [55]. Of note, RAS blockade by
angiotensin receptor blockers or angiotensin converting enzyme in-
hibitors was the ﬁrst eﬀective anti-ﬁbrotic drug that proved eﬃcient to
alleviate the progression of renal ﬁbrogenesis [62].
In addition, oxidative stress is also implicated in the pathogenesis of
renal damage [63] and TGF-β-induced RAS activation displays huge
potency in disease progression [64]. The resolution of angiotensin II-
induced kidney damage and ﬁbrosis in animal models provides addi-
tional evidence to the fact that restraining RAS signaling cascade has
made survival possible for patients with kidney diseases [65].
Oxidative stress/RAS axis also contributes to diabetic nephropathy
[4], underscoring the importance of oxidative stress/RAS axis blockade
in the treatment of patients with diabetic nephropathy. Notably, a
careful understanding of the underlying mechanisms about oxidative
stress modulation is prerequisite before reaching clinical application as
oxidant species are dynamically altered. Moreover, RAS, especially for
angiotensin II/angiotensin II type 1 receptor axis, accelerated renal
damage with aging via ROS generation [66], providing new insight into
disease prevention.
2.4. Nrf2 signaling
Nrf2, an inducible transcription activator, is generally recognized as
a master mediator of variant detoxiﬁcation responses as well as redox
homeostasis and provides cytoprotection from oxidative stresses or
xenobiotic [67,68]. Anti-oxidant responses are modulated by Nrf2 sig-
naling pathway in combination with Kelch-like ECH-associted protein 1
(Keap1), resulting in the elevated expression of a series of anti-oxidant
factors to counterbalance oxidative stress, such as haem oxygenase 1,
glutathione S-transferase and c-glutamylcysteine synthetase etc [69].
Under basal conditions, Nrf2 predominantly exists in the cytoplasm as a
temporarily inactive complex via bounding to Keap1, a repressor mo-
lecule that positively associated with Nrf2 ubiquitination [70], while
Keap1 alkylation facilitates the accumulation of Nrf2 synthesis as well
as its translocation to nucleus in oxidative milieu [70–73]. Within the
nucleus, Nrf2 combines with the regulatory sequences of the genes in
charge of anti-oxidant and detoxifying molecules, which were known as
electrophile response elements or anti-oxidant response elements.
Given the role of Nrf2 impairment in CKD-induced inﬂammation
and oxidative stress [74], there are numerous studies demonstrated that
pharmacological development aimed at enhancing Nrf2 expression
might be exploited for preventing not only renal diseases but also
myriad other pathology obstacles in which oxidative stress played a
particularly paramount role in pathogenesis [4,75]. Additionally, Xiao
et al. highlighted that Nrf2 restoration and Keap1 inhibition dramati-
cally ameliorated tubular injury induced by mitophagy in animal
models of diabetes, underscoring Nrf2 may be a potential therapeutic
target for kidney damage [76]. Keap1-null mouse is an ideal model to
investigate Nrf2 activity since Keap1 tightly represses Nrf2 signaling
pathway in normal conditions, while Keap1-null mice frequently die of
oesophageal hyperkeratosis due to Nrf2 hyperactivation, which se-
verely restricts Nrf2 investigation. Fortunately, the emerging mouse
model, oesophageal Nrf2-defective and systemic Keap1-null mice, ex-
hibits high Nrf2 expression due to Keap1 deﬁciency but without juve-
nile lethality or oesophageal hyperkeratosis, fueling considerable en-
thusiasm for a better understand of cytoprotective defense systems
[77].
In addition, there are numerous studies highlighted that persistent
ﬁbrosis in aging might be associated with the redox imbalance between
Nox4 and Nrf2 [78,79]. The prevalence of pathological ﬁbrosis was
increased with advanced age through the loss of Nox4-Nrf2 redox
homeostasis and aged mice showed an impaired potential for ﬁbrosis
reversal, underscoring the importance of Nox4-Nrf2 restoration in
therapeutic intervention [80,81]. Nonetheless, although Nrf2 pre-
servation might be plausible in impeding persistent ﬁbrosis, there is a
severe paucity of relevant studies on renal ﬁbrosis and their clinical use
remains a tremendous challenge.
2.5. PPARγ signaling
PPARγ is a ligand-dependent transcription factor that plays critical
roles in various metabolic processes besides signiﬁcant anti-in-
ﬂammatory eﬀect [82]. Emerging evidence suggested that PPARγ was
involved in redox equilibrium [83] and PPARγ agonist showed pro-
tective potential against oxidative stress [84]. PPARγ was of paramount
importance to the maintenance of renal metabolic homeostasis, the
defectiveness of which exacerbated nephropathy/renal ﬁbrosis, in-
dicating PPARγ preservation might be pursued for pharmaceutical ex-
ploitation. Additionally, PPARγ interacted with TGF-β1 as well. TGF-β1
could downregulate PPARγ via miR-130a/301b in vascular smooth
muscle cells, whereas PPARγ inhibited glucose metabolism through
mediating TGF-β1/Smad3, hinting PPARγ was a promising target with
particular promise to terminate ﬁbrogenesis [62].
Except for above-mentioned factors, Klotho, an anti-aging protein
primarily expressed in the kidney, is a target gene of PPARγ that in-
timately associated with the development and the progression of renal
diseases [85], which makes advanced age more preventable than in-
evitable. The aging kidney is susceptible to variant kidney damage [86]
and PPARs has been instrumental for myriad age-related inﬂammatory
responses including renal diseases [87]. The probability of harbouring
kidney injury is higher in animal models or patients with Klotho loss
and Klotho preservation could protect kidney against various patholo-
gical milieu [85], highlighting the importance of Klotho intervention in
therapeutic strategy development. Nevertheless, although PPARγ ago-
nists have been shown to reverse or prevent kidney damage, there is
still a paucity of randomized clinical trials to further elucidate the
safety and eﬃcacy of these molecules, which severely retards their use.
2.6. AGEs
AGEs and the receptor for AGEs (RAGE) are inseparably involved in
renal inﬂammation and oxidative stress [88]. Chronic or sustained
hyperglycaemia led to the non-enzymatic covalent bonding of a series
of carbohydrates as exempliﬁed by glucose, to lipids and proteins in a
physiological process known as glycation [89]. Glycation products that
formed in the short term could combine to generate cross-linked
structures recognized as AGEs. These modiﬁed lipids and proteins were
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closely associated with RAGE and triggered a signaling cascade through
which ROS generation and nuclear factor-κB (NF-κB) activation. Ad-
ditionally, there is a vicious cycle since NF-κB could upregulate RAGE
expression as well, accelerating further cytokine and ROS synthesis
[90].
Myriad studies highlighted that oxidative stress was a major
etiology of diabetic nephropathy [4], and AGE-RAGE signaling pathway
played crucial roles in the pathogenesis via exacerbating ROS genera-
tion [91], which had been recognized as one of the ﬁve cellular and
molecular mechanisms of redox signaling in diabetic complications [4].
In addition, AGE inhibition or RAGE knockout could dramatically at-
tenuate renal damage caused by redox molecular mechanisms as well as
the production of numerous pro-inﬂammatory cytokines [92], hinting
AGE-RAGE-ROS axis intervention might be investigated for preventing
or harnessing diabetic nephropathy through alleviating oxidative stress.
Unfortunately, thus far, the precise process of AGE/RAGE on ROS
generation remained elusive due to the severely limited investigations,
but there is a growing body of evidence suggested that AGE-RAGE
signaling contributed much to NOX activation [19].
Apart from above-mentioned factors, AGE overexpression was as-
sociated with nondiabetic progression of renal disorders as well, such as
obesity [93] and advanced age [94]. RAGE knockout could facilitate
damage recovery, underscoring the importance of RAGE blockade as a
potential therapeutic approach [94,95]. Of note, although the fact that
a reduction of RAGE has been instrumental to protect against obese and
aging in mice is plausible, deeper studies remain to be determined since
available animal models often cannot fully recapitulate relevant human
diseases, and thus promising therapies that lead to damniﬁcation re-
gression may not directly translate into strategy in humans.
2.7. MicroRNAs
Functional studies have shown that microRNA dysregulation is
causal in myriad diseases, with microRNAs acting as activators or
suppressors, and insight into the roles of microRNAs in disease pro-
gression has made microRNAs attractive targets of therapeutic mod-
alities [96–99]. Here, we only highlight microRNA-21, -205 and -153
that play pivotal roles in renal disorders.
Numerous studies indicated that microRNA-21 contributed to the
pathogenesis of ﬁbrosis in multiple organs as exempliﬁed by the kidney
via mediating metabolic pathways that were of prominent signiﬁcance
to ROS production as well as ATP generation and inﬂammatory sig-
naling [100], while microRNA-21 inhibition or knockout could protect
against ﬁbrogenesis in response to renal injury [101]. Moreover, ﬁ-
brosis-associated microRNA-21 was the most upregulated microRNAs
in animal models of allogenic kidney transplantation, the antagonism of
which had beneﬁcial eﬀects on chronic renal allograft dysregulation,
highlighting microRNA silencing might be a promising therapeutic
option in patients following kidney transplantation via halting the
progression of chronic renal allograft dysfunction [102]. Nonetheless,
the emerging consensus that both overexpression and suppression of
microRNA-21 could accelerate basal as well as maximal mitochondrial
respiration is increasingly recognized [103], which is quite distinct
from that of previous investigations. Collectively, thus far, there is a
paucity of relevant studies about the optimal level of microRNA-21 in
clinical use, and the therapeutic eﬃcacy of microRNA-21 silencing in
human beings remains a tremendous challenge due to the severely
limited investigations.
A reduction of microRNA-205 in cells was susceptible to oxidative
stress, the supplementation of which alleviated renal damage, sug-
gesting microRNA-205 may be a novel therapeutic target for acute
kidney injury and chronic kidney disease [104]. Astonishingly, this is
the only time that microRNA-205 has been studied in renal tubular cells
under oxidative stress, and the eﬃcacy of microRNA-205 in reversing
kidney damage remains to be determined. Liu et al. uncovered Pb-in-
duced redox signaling in rat kidney was attenuated by grape seed
procyanidin extract treatment through Nrf2 signaling pathway activa-
tion and microRNA-153 suppression for the ﬁrst time [105], providing
new insight into the prevention and regression of Pb-induced ne-
phrotoxicity. Unfortunately, although the anti-oxidation of grape seed
procyanidin in lessening kidney injury has been further validated in a
series of studies, the potential of microRNA-153 inhibition was rarely
covered, which severely impeded their clinical use [106].
2.8. Vitagenes
Oxidative stress may contribute to aging kidney and renal diseases
via modulating vitagene system. Vitagene system is responsible for the
generation of cytoprotective heat shock proteins and protects against
oxidative stress by acting as a paramount intracellular redox system
[107]. Redox signaling devotes much to cognitive impairment
[108,109] and targeted therapeutics aiming at restricting age-related
changes could facilitate clinical outcomes as well as survival beneﬁt
[110,111]. Mounting evidence has shed light on the unexpected role of
vitagenes in mediating aging and neurodegenerative diseases imparted
by heat shock proteins [112], which dramatically expands our arma-
ments beyond traditional strategies to win more battles against ad-
vanced age.
Considering the prominent relationship of vitagene restoration and
long-term survival in neurodegenerative diseases by mitigating free
radical-induced cellular damage [112–114], it is highly reasonable to
postulate that therapeutically targeting vitagenes portend a novel
paradiagm in anti-oxidant modalities, which may aid our under-
standing between redox signaling and aging kidney. Unfortunately,
thus far, there is a paucity of suﬃcient knowledge of vitagenes on renal
diseases since the dominant view of the anti-oxidative eﬀects of vita-
genes weighs heavily towards neurodegenerative diseases. Therefore,
deeper investigations are expected to progress toward therapeutic de-
velopment for the intervention of kidney disorders.
3. Therapeutic opportunities for natural products in aging kidney
and kidney disease
Natural products and their relevant secondary metabolites have
been proven to be the fertile ground for drug discovery and pharma-
ceutical exploitation [31,62,115]. Moreover, recent advances of pow-
erful analytical platforms based on genomics, proteomics and metabo-
lomics as well as bioinformatics have been ubiquitously employed to
reveal the bioactivities of myriad natural products [116–119]. A
growing body of studies supported that natural products should be re-
visited since the side eﬀects of available commercial drugs brought risks
and severely restricted their use. Actually, about half of drugs that
approved by FDA from 1981 to 2014 were recognized to be natural
products and their derivatives [120]. In this scenario, we demonstrate a
series of compounds that were isolated from natural products with
therapeutic potentials in patients with aging kidney and kidney disease
by interfering with above-mentioned mediators (Table 1).
Diabetic nephropathy is deeply implicated in the etiology of end-
stage renal disease, and therapeutic strategies for restraining its pro-
gression remain limited [16,121]. Although molecular signaling me-
chanisms that contributed to the progression of diabetic nephropathy
had been elucidated, various nephroprotective agents with promising
future were failed in clinical trials, underscoring an insuﬃcient un-
derstanding of pathological pathways [122]. In addition, oxidative
stress played pivotal roles in the pathogenesis of diabetic nephropathy
and a thorough comprehension of oxidative stress may pave the way for
the advancement of therapeutic agents against diabetic nephropathy
[4]. The important ﬁndings of natural products against diabetic ne-
phropathy were described [123,124]. Scutellarin [125] as well as
Schisandrin B [126] and myrciaria cauliﬂora extracts [127] could alle-
viate diabetic nephropathy by activating Nrf2 or inhibiting RAS sig-
naling pathway. Moutan Cortex had therapeutic eﬀects against kidney
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dysregulation via TGF-β in rats with diabetic nephropathy [128].
Moreover, AGE-RAGE was also intimately involved in the progresion of
diabetic nephropathy, and diphlorethohydroxycarmalol, a polyphenol
isolated from Ishige okamurae, alleviated renal damage through pre-
venting AGE generation in HEK cells, which might be pursued for po-
tential therapeutic agent in patients with diabetic nephropathy [129].
Hou et al. demonstrated that Salvianolic acid A prevented from diabetic
nephropathy by restraining AGE-RAGE-NOX4 with validated safety for
the ﬁrst time [19], which dramatically accelerated the advances of drug
discovery since myriad compounds concerning AGE-RAGE inhibition
and diabetic nephropathy regression had been withdrawn from clinical
trials due to its unsatisfactory safety [130]. Resveratrol [131,132],
kaempferitrin [133] and chrysin [134] could reduce renal damage
through AGE/RAGE or Nrf2-Keap1 in animal models of diabetic ne-
phropathy. Additionally, resveratrol also played paramount roles in
protecting against diabetic renal ﬁbrosis [135], aging kidney [66] and
kidney damage [136,137] in animal models. Nevertheless, the clinical
application of resveratrol remains a tremendous challenge due to the
unfavorable pharmacokinetic and biochemical properties, while re-
sveratrol conjugates may portend a novel paradigm in the development
of pharmaceutical exploitation, which has been proved to be more ef-
ﬁcacious than resveratrol in human neuroblastoma SH-SY5Y cells
[138].
Fibrosis is a chronic process in response to excessive inﬂammation
and epithelial injury, and represents the common process of nearly all
progressive nephropathies [34]. Nrf2-Keap1 is of great signiﬁcance to
ﬁbrosis resolution and curcumin aimed at restoring Nrf2 activity could
eﬀectively attenuate ﬁbrogenesis in animal models with 5/6 ne-
phrectomy [139]. TGF-β and RAS also play vital roles in the patho-
genesis of ﬁbrosis [32]. Mou et al. demonstrated that Schisandrin B
could retard renal ﬁbrosis via inhibiting TGF-β signaling for the ﬁrst
time [126], providing additional evidence to previous studies. Our
previous studies uncovered that some diuretic traditional Chinese
medicines, such as Alisma orientale (Sam.) Juzep. [140–142] and Poria
cocos (Schw.) Wolf (Polyporaceae) [143–149], showed good ther-
apeutic eﬀects on ﬁbrosis. Poricoic acid ZG and ZH exhibited strong
inhibitory eﬀects against renal ﬁbrosis compared with poricoic acid ZF
via modulating TGF-β/Smad3 and angiotensin II, which might be
caused by their diverse chemical structures in carboxyl groups and the
ﬁrst six-membered ring [150]. Additionally, given the incomplete eﬃ-
cacy of traditional RAS blockader in renal diseases, it is of paramount
signiﬁcance to develop novel therapies that simultaneously target
multiple RAS components. Poricoic acid ZA signiﬁcantly mitigated tu-
bulointerstitial ﬁbrosis through inhibiting the upregulation of renin,
angiotensinogen, angiotensin converting enzyme, angiotensin II type 1
receptor and TGF-β/Smad pathway [18]. The secolanostane tetracyclic
triterpenoids poricoic acid ZC and ZD eﬀectively protected against renal
ﬁbrosis by simultaneously targeting all RAS components than lanostane
tetracyclic triterpenoid poricoic acid ZE, indicating compounds with
secolanostance skeletons might perform better against ﬁbrogenesis than
those with lanostance skeletons, which may be exploited for novel RAS
inhibitors [151]. Moreover, 25-O-Methylalisol F, isolated from Alisma
orientale, could attenuate tubulointerstitial ﬁbrosis by targeting mul-
tiple RAS components without remarkable proliferative or cytotoxic
eﬀect on NRK-52E cells, providing new insight into the development of
novel therapeutic intervention against ﬁbrosis and RAS blockade [17].
Natural products also retarded chronic kidney disease [152], renal
failure [153,154] and nephrotoxicity [155]. Salvia miltiorrhiza Bunge is
a natural product with a thousand years of clinical application [156].
Salvia miltiorrhiza extract could signiﬁcantly alleviate adenine-induced
chronic renal failure through NOX/ROS and TGF-β/Smad signaling
pathways [157], which oﬀers additional evidence for the incorporation
of natural products into the future study against chronic renal failure.
Poricoic acid A, isolated from Poria cocos, lessened chronic kidney
disease [158] and the transition of acute kidney injury to chronic
kidney disease by regulating Nrf2 signaling cascade [159]. Ergone, a
major compound of Polyporus umbellatus, halted tubular damage and
further prevented tubulointerstitial ﬁbrosis through blocking TGF-β
signal transducer [160]. Furthermore, the burden of myriad diseases
attributable to heavy metal pollution is becoming a global health pro-
blem [161]. Studies aimed at investigating the relationship of natural
products as well as oxidative stress and metal-induced kidney diseases
Table 1
Summary of primary natural products in aging kidney and kidney disease.
Natural products Resources Model Therapeutic target Refs
Diabetic nephropathy
Scutellarin Erigeron breviscapus Mice AGEs inhibition and Nrf2 promotion [125]
Schisandrin B Schisandra chinensis Mice Nrf2 activation [126]
Myrciaria cauliﬂora extracts Myrciaria cauliﬂora Mice RAS regulation [127]
Moutan Cortex Paeonia suﬀruticosa Rats TGF-β inhibition [128]
Salvianolic acid A Salvia miltiorrhiza Rats AGE/RAGE/NOX4 inhibition [19]
Diphlorethohydroxycarmalol Ishige okamurae HEK cells AGE inhibition and Nrf2 activation [129]
Resveratrol Plants Rats RAGE inhibition [131]
Grapevines; berries Rats Nrf2-Keap1 regulation [132]
Kaempferitrin Plants Rats AGE/RAGE and TGF-β inhibition [133]
Chrysin Passion ﬂowers; honey; mushroom Mice AGE/RAGE and TGF-β inhibition [134]
Aging kidney
Resveratrol Plants Mice Angiotensin II inhibition [66]
Renal ﬁbrosis
Schisandrin B Schisandra chinensis Mice TGF-β inhibition [126]
Resveratrol Mice NOX4/ROS regulation [135]
Curcumin Turmeric Rats Nrf2-Keap1 regulation [139]
Poricoic acid ZA Poria cocos HK-2 cells RAS and TGF-β/Smad pathway inhibition [18]
Poricoic acid ZF, ZG and ZH Poria cocos HK-2 cells RAS and TGF-β/Smad3 inhibition [150]
Poricoic acid ZC and ZD Poria cocos HK-2 cells RAS inhibition [151]
Poricoic acid ZE Poria cocos HK-2 cells Renin inhibition [151]
25-O-methylalisol F Alisma orientale Rats RAS and TGF-β/Smad3 inhibition [17]
Renal damage
Resveratrol Grapes; berries; red wines; peanut skins NRK-52E cells Nrf2 activation [136]
Salvia miltiorrhiza extract Salvia miltiorrhiza Rats/HK-2 cells NOX/ROS and TGF-β/Smad regulation [157]
Poricoic acid A Poria cocos Rats Nrf2 regulation [158,159]
Ergone Polyporus umbellatus Rats TGF-β regulation [160]
Nephrotoxicity
Procyanidin extract Grape seed Rats Nrf2 activation and microRNA153 inhibition [105]
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may aid the development of pharmaceutical exploitation. Liu et al.
demonstrated that grape seed procyanidin extract had the potential to
mitigate Pb-induced oxidative stress via suppressing microRNA-153
and activating Nrf2 signaling pathway for the ﬁrst time, providing new
therapeutic targets for Pb-induced nephrotoxicity [105]. Unfortunately,
although the extracts of Salvia miltiorrhiza and grape seed procyanidin
have made survival possible for patients with chronic renal failure and
nephrotoxicity, there is a paucity of suﬃcient knowledge on active
ingredients and their potential adverse eﬀects, which severely restricts
the clinical use.
4. Concluding remarks
Kidney disease is a global burden that severely impedes renal
function with aging regardless of the etiology, and a thorough under-
standing of pathological mechanisms may permit the disease resolution.
Oxidative stress plays a pivotal role in the pathogenesis of myriad renal
disorders, while the clariﬁcation of underlying mechanisms remains
elusive, indicating deeper studies are urgently needed. In this review,
we expatiated some important advances in mediators of aging kidney
and kidney disease that might be amenable to the development of
therapeutic targeting, including NOX, TGF-β, RAS, Nrf2, PPARγ, AGEs
as well as microRNAs and vitagenes.
Of note, given the serious side eﬀects of existing commercial drugs,
natural products are increasingly recognized as an emerging alternative
source for drug discovery. We highlight a number of natural products
with prominent therapeutic eﬀects in aging kidney and kidney diseases
by interfering above-mentioned factors. A series of poricoic acids, iso-
lated from Poria cocos, and Salvia miltiorrhiza extract have been studied
in human kidney proximal epithelial cells. In addition, the therapeutic
eﬀect of diphlorethohydroxycarmalol was investigated in human em-
bryonic kidney cell lines as well. Notably, poricoic acids showed no
remarkable cytotoxic eﬀect on HK-2 cells at the therapeutic dosage,
fueling considerable enthusiasm for natural products as promising
treasure trove of drug discovery, particularly within the arena of anti-
ﬁbrotic studies. Moreover, recent success in technical advances, illu-
strated by metabolomics-guided fractionation tools, has brought re-
newed enthusiasm that the bioactive structure of natural products may
be screened at the fractionation with the help of databases [162], which
predominantly reduces the cost of drug development. Additionally, it is
generally accepted that reverse pharmacokinetics helps clariﬁcate key
questions in drug discovery from various natural products with proven
clinical beneﬁts [163], dramatically facilitating the pace of active in-
gredient in clinical practice since a substantial portion of natural pro-
ducts are used as extracts. Nonetheless, given the fact that available
animal models cannot adequately recapitulate human diseases, current
eﬀective treatment of other natural products in animal models might
not directly translate into therapies in humans and relevant studies
remains to be determined, which is prerequisite before clinical appli-
cation.
Undoubtedly, natural product is a precious treasure trove for new
drug discovery, while some issues severely restrict their development.
The most diﬃcult obstacle is the paucity of well-designed, randomized,
placebo-controlled trials in humans, which make it hard to reach clin-
ical application. Additionally, the safety of natural products is another
crucial issue since natural products are primarily used as extracts or
prescription, while the active ingredients are rarely covered.
Considering the fact that natural product cannot be utilized in humans
until proper clinical evidence, there is intense impetus to combine
pharmacological exploitation with the identiﬁcation of bioactive com-
ponents. Once these impediments are eradicated, utilizing natural
products as an alternative source to exploit new drug will be at hand.
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